Mayne Pharma Group Ltd
ASX:MYX
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
3.81
7.37
|
Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one MYX stock under the Base Case scenario is 8.43 AUD. Compared to the current market price of 4.48 AUD, Mayne Pharma Group Ltd is Undervalued by 47%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Mayne Pharma Group Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for MYX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Mayne Pharma Group Ltd
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Mayne Pharma Group Ltd
Balance Sheet Decomposition
Mayne Pharma Group Ltd
Current Assets | 460.6m |
Cash & Short-Term Investments | 151.6m |
Receivables | 207.7m |
Other Current Assets | 101.3m |
Non-Current Assets | 682.6m |
PP&E | 53.3m |
Intangibles | 568.6m |
Other Non-Current Assets | 60.7m |
Current Liabilities | 313.9m |
Accounts Payable | 20.9m |
Accrued Liabilities | 179.9m |
Other Current Liabilities | 113.2m |
Non-Current Liabilities | 375.1m |
Long-Term Debt | 35m |
Other Non-Current Liabilities | 340.1m |
Earnings Waterfall
Mayne Pharma Group Ltd
Revenue
|
395.5m
AUD
|
Cost of Revenue
|
-169.6m
AUD
|
Gross Profit
|
225.8m
AUD
|
Operating Expenses
|
-381.1m
AUD
|
Operating Income
|
-155.3m
AUD
|
Other Expenses
|
-18.9m
AUD
|
Net Income
|
-174.2m
AUD
|
Free Cash Flow Analysis
Mayne Pharma Group Ltd
AUD | |
Free Cash Flow | AUD |
MYX Profitability Score
Profitability Due Diligence
Mayne Pharma Group Ltd's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
Score
Mayne Pharma Group Ltd's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
MYX Solvency Score
Solvency Due Diligence
Mayne Pharma Group Ltd's solvency score is 56/100. The higher the solvency score, the more solvent the company is.
Score
Mayne Pharma Group Ltd's solvency score is 56/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MYX Price Targets Summary
Mayne Pharma Group Ltd
According to Wall Street analysts, the average 1-year price target for MYX is 6.21 AUD with a low forecast of 5.99 AUD and a high forecast of 6.56 AUD.
Dividends
Current shareholder yield for MYX is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
MYX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Mayne Pharma Group Ltd. engages in the development and manufacture of proprietary and generic products. The company is headquartered in Adelaide, South Australia. The company went IPO on 2007-06-29. The Company’s segments include Generic Products (GPD), Specialty Products (SPD), Metrics Contract Services (MCS), and Mayne Pharma International (MPI). The GPD segment is engaged in the distribution of generic pharmaceutical products in the United States. GPD segment engaged in the distribution of generic pharmaceutical products in the United States. MCS segment is providing contract pharmaceutical development and manufacturing services to third party customers principally in the United States. SPD segment is distributing specialty pharmaceutical products in the United States. MPI segment manufactures and sells branded and generic pharmaceutical products globally and provisions of contract manufacturing services to third party customers within Australia.
Contact
IPO
Employees
Officers
The intrinsic value of one MYX stock under the Base Case scenario is 8.43 AUD.
Compared to the current market price of 4.48 AUD, Mayne Pharma Group Ltd is Undervalued by 47%.